Investor Overview

Corporate Profile
Histogenics is a regenerative medicine company focused on developing and commercializing products in the musculoskeletal segment of the marketplace. Our regenerative medicine platform combines expertise in cell processing, scaffolding, tissue engineering, bioadhesives and growth factors to provide solutions that can be utilized individually or in concert to treat musculoskeletal-related conditions. Our first investigational product candidate, NeoCart®, leverages our platform to provide an innovative treatment in the orthopedic space, specifically cartilage damage in the knee. For more information on Histogenics, please visit the company website at www.histogenics.com.
Stock Quote
HSGX (Common Stock)
ExchangeNASDAQ (US Dollar)
Financial Status IndicatorD
Price$1.79
Change (%) Stock is Down 0.01 (0.56%)
Volume53,046
Data as of 06/28/17 4:00 p.m. ET
Minimum 20 minute delay
Refresh quote
Recent NewsMore >>
DateTitle 
06/27/17Histogenics Completes Enrollment for Phase 3 Clinical Trial of Neocart® to Treat Knee Cartilage Damage
– On Track for Top-Line One Year Superiority Data and Potential BLA Filing in Third Quarter of 2018 – Articular cartilage can be damaged by injury or normal wear and tear (http://www.neocartimplant.com/cartilage-injury). – Novel Tissue Implant Potentially Ac... 
Printer Friendly Version
06/05/17Histogenics Corporation Announces the Appointment of Donald Haut, Ph.D. as Chief Business Officer
‒ Experienced Biotechnology Business Development & Strategic Planning Executive to Lead Commercial Partnership Activities ‒ WALTHAM, Mass., June 05, 2017 (GLOBE NEWSWIRE) -- Histogenics Corporation (Histogenics) (Nasdaq:HSGX), a regenerative medicine company focused on developing and commercializing products in the musculoskeletal space, announced the appointment of Donald Haut, Ph.D. as its Chief Business Officer.  Dr. Haut brings more than 20 years of executive management experience in ... 
Printer Friendly Version
05/16/17Histogenics Corporation to Present at Upcoming Industry Conferences
WALTHAM, Mass., May 16, 2017 (GLOBE NEWSWIRE) -- Histogenics Corporation (Histogenics) (Nasdaq:HSGX), a regenerative medicine company focused on developing and commercializing products in the musculoskeletal space, today announced that Management will be presenting at several upcoming industry conferences.  12th World Advanced Therapies & Regenerative Medicine Congress – London, England (May 17-19, 2017) Adam Gridley, Histogenics’ CEO, will be participating in several panels disc... 
Printer Friendly Version
05/15/17Histogenics Corporation Receives Innovation Award
‒ Histogenics Recognized by the Smaller Business Association of New England (SBANE) as One of the Most Innovative Companies in the Region ‒ ‒ NeoCart® and Tissue Generation Platform Seen as a Potential Leading Solution to Treat Cartilage Defects ‒ WALTHAM, Mass., May 15, 2017 (GLOBE NEWSWIRE) -- Histogenics Corporation (Histogenics) (Nasdaq:HSGX), a regenerative medicine company focused on developing and commercializing products in the musculoskeletal space, announced that it was one of the ... 
Printer Friendly Version
Upcoming EventsMore >>
There are currently no events scheduled.
Contact Information

Histogenics Corporation
Phone: 781.547.7900
E-mail: InvestorRelations@histogenics.com

Featured Documents
View the Company Profile
Receive E-mail AlertsE-mail Alert Icon
Sign up to receive e-mail alerts whenever Histogenics Corp posts new information to the site. Just enter your e-mail address and click Submit.
 

Replication or redistribution of EDGAR Online, Inc. content is expressly prohibited without the prior written consent of EDGAR Online, Inc. EDGAR Online, Inc. shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.